Markus is the CSO at Celeris Therapeutics, an AI-first drug discovery startup from Graz, Austria that aims to discover novel bivalent degraders based on our Celeris One computational platform. Prior to Celeris he was the Chief Technology Officer and head of R&D at PhoreMost, a Cambridge UK Biotech with a novel target discovery platform to drug previously undruggable targets. Markus has a background in engineering, IT and Life sciences. He has a PhD from the Medical University of Vienna (Medical Chemistry) that was followed by a postdoc at the Center for Molecular Medicine (CeMM) with BROAD institute alumni Sebastian Nijman.